:: Library Catalog

Imagen de Portada

Guardado en:

Detalles Bibliográficos
Autor principal:	Iskandar Idris
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Diabetes, Obesity and Metabolism Now
Acceso en línea:	https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1002/doi2.108
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Epigenetic changes shown to cause type 2 diabetes
por: Iskandar Idris
Publicado: (2024)

Tirzepatide shown to be effective at reducing sleep disturbances in patients with obstructive sleep apnoea
por: Iskandar Idris
Publicado: (2024)

Increasing excess to weight loss injection shown to save thousands of lives a year
por: Iskandar Idris
Publicado: (2024)

Tirzepatide shown to improve clinical outcomes for patients with heart failure with preserved ejection fraction (HFpEF) and obesity
por: Iskandar Idris
Publicado: (2024)

Glucagon like peptide‐1 (GLP‐1) therapy is associated with reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes with chronic liver disease
por: Iskandar Idris
Publicado: (2024)

Appropriate timing of exercise for adults with obesity including those with type 2 diabetes
por: Iskandar Idris
Publicado: (2024)

Potential role of glucagon like peptide (GLP)‐1 receptor agonist to reduce risk of colorectal cancer?
por: Iskandar Idris
Publicado: (2024)

Precision medicine approach to detect obese people who are at high risk of developing diabetes
por: Iskandar Idris
Publicado: (2024)

Can diet and exercise intervention prevent type 2 diabetes in individuals with a high genetic risk?
por: Iskandar Idris
Publicado: (2024)

Hybrid closed‐loop therapy significantly improved maternal glucose control during pregnancy complicated by type 1 diabetes
por: Iskandar Idris
Publicado: (2024)

Extension study from DIRECT showed ongoing remission rate from type 2 diabetes in some patient following very low calorie diet at 5 years
por: Iskandar Idris
Publicado: (2024)

The glucagon like peptide‐1 linked to nonarteritic anterior ischemic optic neuropathy
por: Iskandar Idris
Publicado: (2024)

Adults who are overweight or obese may experience greater pain intensity compared with normal weight individuals?
por: Iskandar Idris
Publicado: (2024)

The US Food and Drug administration has approved resmetirom as the first drug to treat metabolic dysfunction‐associated steatohepatitis (MASH)
por: Iskandar Idris
Publicado: (2024)

Potential new therapies to preserve lean muscle mass loss when used in combination with glucagon‐like peptide 1 (GLP‐1) receptor agonist being studied
por: Iskandar Idris
Publicado: (2024)

Real world study provided reassurance of the safety of GLP‐1 therapy on mental health and suicide risk
por: Iskandar Idris
Publicado: (2024)

Real world data showed that the dual GLP gip agonist, Tirzepatide is associated with lower mortality, cardiovascular events and adverse kidney events compared with GLP‐1 analogue
por: Iskandar Idris
Publicado: (2024)

Increased expression of the protein Kallistatin after weight loss induces beneficial metabolic effects: A potential new therapeutic target?
por: Iskandar Idris
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

The latest evidence and guidance in lifestyle and surgical interventions to achieve weight loss in people with overweight or obesity
por: Iskandar Idris, et al.
Publicado: (2025)

Semaglutide attenuates diabetic retinopathy progression via ameliorating retinal vasculopathy and oxidative stress in vivo and in vitro
por: Xiao Cheng, et al.
Publicado: (2025)

Effect of tirzepatide on the risk of diabetic retinopathy in type 2 diabetes
por: Djordje S. Popovic, et al.
Publicado: (2024)

Association between time in tight range and incident diabetic retinopathy in adults with type 2 diabetes
por: Yaxin Wang, et al.
Publicado: (2024)

Risk of diabetic retinopathy and ophthalmic interventions in patients with diabetes mellitus taking different oral anticoagulants
por: Hou‐Ren Tsai, et al.
Publicado: (2025)

Overweight or obesity, weight variability and the risk of retinopathy in type 1 diabetes
por: Thomas Nyström, et al.
Publicado: (2024)

Clinical observation and experimental study on the role of choroid‐to‐retina volume ratio in diabetic retinopathy
por: Jian Zhao, et al.
Publicado: (2025)

Incidence and progression of diabetic retinopathy in patients treated with glucagon‐like peptide‐1 receptor agonists versus sodium‐glucose cotransporter 2 inhibitors: A population‐based cohort study
por: Donna Shu‐Han Lin, et al.
Publicado: (2024)

MicroRNA ‐mediated Ets1 repression in retinal endothelial cells: A novel anti‐angiogenic mechanism in nonproliferative diabetic retinopathy
por: Jianyu Zhao, et al.
Publicado: (2025)

Integrative metabolomic and proteomic analysis of diabetic kidney disease progression with younger‐onset type 2 diabetes
por: Resham Lal Gurung, et al.
Publicado: (2025)

Global, regional and national burden of blindness and vision loss attributable to diabetic retinopathy, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2021
por: Yujie Pan, et al.
Publicado: (2025)

Real‐world impact of tirzepatide on the risk of progression to type 2 diabetes and metabolic outcomes in people with obesity and pre‐diabetes
por: Scott A. Coon, et al.
Publicado: (2025)

Real‐world predictors of progression to type 2 diabetes among adults with prediabetes
por: Tyler Dunn, et al.
Publicado: (2026)

The protective role of TIGIT + B cells in attenuating type 1 diabetes progression
por: Yiman Peng, et al.
Publicado: (2025)